New Hope for Sudden Hearing Loss: AudioCure Secures Funding

Berlin-based pharmaceutical startup AudioCure has secured significant new funding to advance its promising hearing loss treatment, as announced in a press release by High-Tech Gründerfonds (HTGF). InfectoPharm, a successful mid-sized German pharmaceutical company specializing in ENT treatments, is leading the latest financing round.

The investment will accelerate the development of AC102, AudioCure's drug candidate currently in Phase 2 clinical trials across Europe. What makes this development particularly significant is that there are currently no approved medications for treating sudden hearing loss. In preclinical hearing loss models, AC102 has demonstrated remarkable results, nearly fully restoring hearing ability and outperforming traditional corticosteroid therapies.

Dr. Reimar Schlingensiepen, Managing Director of AudioCure, emphasized the perfect synergy between the partners. The company now benefits from both financial support and extensive expertise, with InfectoPharm and existing investor MED-EL bringing over 30 years of ENT experience to the table.

The drug has already successfully passed human safety and tolerability tests in Phase 1 trials. AudioCure is also developing treatments for tinnitus and solutions to support residual hearing in cochlear implant users, positioning itself as a pioneer in addressing various hearing-related conditions.